Complementary Therapies in Inflammatory Bowel Diseases

被引:8
|
作者
Esters, Philip [1 ]
Dignass, Axel [1 ]
机构
[1] Goethe Univ Frankfurt, Agaples Markus Hosp, Dept Med 1, D-60054 Frankfurt, Germany
关键词
Ayurveda; complementary therapies; inflammatory bowel diseases; phosphatidylcholine; probiotics; traditional chinese medicine; ACTIVE ULCERATIVE-COLITIS; PLACEBO-CONTROLLED TRIAL; GERMINATED BARLEY FOODSTUFF; WORMWOOD ARTEMISIA-ABSINTHIUM; RANDOMIZED CONTROLLED-TRIAL; TRICHURIS-SUIS THERAPY; POUCH-ANAL ANASTOMOSIS; CROHNS-DISEASE; DOUBLE-BLIND; MAINTAINING REMISSION;
D O I
10.2174/1389450115666140903112802
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Complementary and alternative therapies (CAM) are defined as therapies that are presently not considered part of conventional medical practice. They are termed "complementary" when used in addition to conventional therapies and termed "alternative" when used instead of conventional therapies. CAM includes many different practices, for example Ayurveda, acupuncture or traditional Chinese medicine (TCM), phytotherapy, homeopathy, probiotics and dietary supplements. While some evidence of benefit exists regarding some therapies, for most of these therapeutic approaches, the therapeutic efficacy and safety have not been proven in well-designed scientific studies. However, the use of complementary and alternative medicine among IBD patients is common, and physicians are frequently confronted with questions about their use. As most of the reported studies contain methodological problems, it is often difficult for physicians to inform their patients adequately. Nevertheless, the widespread use of CAM needs to be recognized. Some of these agents exert plausible biological effects in IBD patients and warrant further investigation. Controlled trials in IBD are warranted to show therapeutic benefits and safety of CAM. This review aims to give a brief overview on the current use of various complementary and alternative treatment options in IBD patients.
引用
收藏
页码:1079 / 1088
页数:10
相关论文
共 50 条
  • [21] Biological therapies and the trajectories of biopsychological factors in inflammatory bowel diseases
    Tavakoli, P.
    Vollmer-Conna, U.
    Campos, X. Vazquez
    Hadzi-Pavlovic, D.
    Grimm, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S296 - S297
  • [22] Biological therapies and the trajectories of biopsychological factors in inflammatory bowel diseases
    Tavakoli, P.
    Vollmer-Conna, U.
    Hadzi-Pavlovic, D.
    Vazquez-Campos, X.
    Grimm, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 108 - 108
  • [23] T-cell-directed therapies in inflammatory bowel diseases
    Monteleone, Giovanni
    Caprioli, Flavio
    CLINICAL SCIENCE, 2010, 118 (11-12) : 707 - 715
  • [24] RETRACTION: Mechanisms and Efficacy of Immunobiologic Therapies for Inflammatory Bowel Diseases
    Ghosh, N.
    Chaki, R.
    Mandal, V
    Lin, G. D.
    Mandal, S. C.
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2024,
  • [25] Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases
    Caprioli, Flavio
    Caruso, Roberta
    Sarra, Massimiliano
    Pallone, Francesco
    Monteleone, Giovanni
    BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (04) : 820 - 828
  • [26] Systematic Review of Complementary and Alternative Medicine Treatments in Inflammatory Bowel Diseases
    Langhorst, J.
    Wulfert, H.
    Lauche, R.
    Klose, P.
    Cramer, H.
    Dobos, G. J.
    Korzenik, J.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (01): : 86 - 106
  • [27] Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
    Song, Hyo Yeop
    Seo, Geom Seog
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (09): : 605 - 613
  • [28] Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning
    Fudman, David I.
    Mcconnell, Ryan A.
    Ha, Christina
    Singh, Siddharth
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2025, 23 (03) : 454 - 468
  • [29] JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases
    Herrera-deGuise, Claudia
    Serra-Ruiz, Xavier
    Lastiri, Ernesto
    Borruel, Natalia
    FRONTIERS IN MEDICINE, 2023, 10
  • [30] Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
    Vetter, Marcel
    Neurath, Markus F.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2017, 10 (10) : 773 - 790